Small molecule · Inhibitor of PI3K alpha (PIK3CA) · developed by Faeth Therapeutics
Serabelisib is an orally bioavailable inhibitor of class I phosphoinositide 3-kinase (PI3K) alpha isoform. It selectively inhibits PI3K alpha kinase, including PIK3CA mutations, in the PI3K/Akt/mTOR pathway to induce tumor cell apoptosis and growth inhibition. It is studied in endometrial cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06463028 | Phase 2 | Endometrial Cancer | Recruiting | FTH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Endometrial Cancer
See FTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FTH catalysts and pipeline →